Navigation Links
Arpida Announces Agenda Items for Shareholders Meeting
Date:4/15/2008

authorised capital) or via conversion of bonds (conditional capital). Arpida currently has no intention to use this capital. This proposed additional capital cannot be used for the granting of employee options.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resi
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
2. Arpida Announces Full Year 2007 Financial Results
3. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida-Supported CME Symposium Available Online
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. Arpida Interim Results for six Months to 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... generation biofuels are a viable solution to the dilemma of ... is very cheap, this is affecting the biofuels market in ... could be in comparison to natural gas. This, in ... for renewable energy developers to get the economics to work ... certain companies have shifted their focused within renewable energy. ...
(Date:7/29/2014)... , July 29, 2014 ... Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery ... - Global Forecasts & Trends to 2018", published by ... restraints in geographies such as North America ... Asia , and the Rest of the World ...
(Date:7/29/2014)... WARRINGTON, Pa. , July 29, 2014 /PRNewswire/ ... company dedicated to advancing a new standard of ... financial results on August 5, 2014 before the ... The Company will host a live teleconference ... day. During the conference call, Discovery Labs, management ...
(Date:7/29/2014)... 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. announced today ... Inc., to provide access to Nanosyn,s microfluidics screening ... platform for novel small molecule therapeutics. ... to work with FORMA Therapeutics to explore key ... homeostasis. FORMA Therapeutics, decision to work with us ...
Breaking Biology Technology:Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Digital Pathology Market worth $437 Million by 2018 2Digital Pathology Market worth $437 Million by 2018 3Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2
... Inc.,(Nasdaq: NGSX ), a biopharmaceutical company focused ... today that,Anthony DiTonno, President and Chief Executive Officer, ... 10th Annual Healthcare Conference in New,York City on ... Ghiglieri,Chief Financial Officer, will also be available to ...
... Company Registered in Switzerland, Will Move its Headquarter ... Various Issues Related to Neovascularisation, - Gene Signal is Working ... Now in Phase III Trials, - Gene Signal Will Present ... the American Academy of Ophtalmologist in Atlanta, USA, the ...
... Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) announced today ... Confab on Tuesday, November,11th at 9:40 a.m. ET., ... be accessed under,"Calendar of Events" in the Idenix Investor ... minutes before the,event to ensure a timely connection. The ...
Cached Biology Technology:NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 2NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference 3Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 2Gene Signal Enters Phase III Clinical Tests for the Prevention of Corneal Graft Rejection 3
(Date:7/29/2014)... , July 29, 2014 Research and ... SaaS-based Business Intelligence (BI) Market 2014-2018" report to ... The term BI refers to applications ... to, or analyzing information about a company,s operations. BI ... affecting their business; for example, metrics on sales, production, ...
(Date:7/29/2014)... But on the remote UK overseas territory of Ascension ... is undergoing something of a renaissance. , Writing in ... the University of Exeter and Ascension Island Government Conservation ... at the remote South Atlantic outpost has increased by ... the 1970s. As many as 24,000 nests are now ...
(Date:7/29/2014)... University of Maryland Schools of Dentistry (UM SOD) ... they have received a five-year $10.7 million grant ... Infectious Diseases (NIAID) of the National Institutes of ... of sexually-transmitted diseases (STDs). The grant, which renews ... represents a new direction for the research by ...
Breaking Biology News(10 mins):Global SaaS-based Business Intelligence (BI) Market 2014-2018 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 2University of Maryland Schools of Dentistry and Medicine receive NIH grant 3University of Maryland Schools of Dentistry and Medicine receive NIH grant 4
... Researchers at Rensselaer Polytechnic Institute have secured ... virtual reality simulator for next-generation "scarless" endoscopic surgery. ... National Institutes of Health (NIH), seeks to accelerate ... or NOTES. This emerging surgical technique shows promise ...
... those battery-pack organelles that fuel the energy of almost ... Whether in a dish or a living organism, the ... Because calcium levels link to many essential biological processesnot ... have been working for half a century to identify ...
... Scientists and educators alike have long known that cramming ... their latest findings, researchers at the RIKEN Brain Science ... mice, have elucidated the neurological mechanism explaining why this ... , their results suggest that protein synthesis in the ...
Cached Biology News:Rensselaer researchers secure $2.7 million NIH grant to advance 'scarless' surgery 2Rensselaer researchers secure $2.7 million NIH grant to advance 'scarless' surgery 350-year search for calcium channel ends 250-year search for calcium channel ends 3A better way to remember 2
... Chain MAP1A and MAP1B are microtubule-associated proteins ... components of the cytoskeleton. MAP1A and MAP1B each ... light chain subunits. The protein encoded by this ... and can associate with either MAP1A or MAP1B. ...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Conveniently document gels, films and membranes with a high quality thermal printer. , Compact, footprint printer , Supplies 256 gray scale for high resolution, archive-quality thermal film prints...
Biology Products: